- Home
- NEUP
as 02-21-2025 4:00pm EST
Stocks
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | EASTWOOD SA |
| Market Cap: | 17.4B | IPO Year: | N/A |
| Target Price: | $21.00 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.12 - $15.72 | Next Earning Date: | 02-14-2025 |
| Revenue: | $662,715 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Neuphoria Therapeutics Inc. Common Stock News
NEUP Breaking Stock News: Dive into NEUP Ticker-Specific Updates for Smart Investing
Compare NEUP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NEUP Neuphoria Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.